Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Janux Therapeutics Inc (NASDAQ: JANX) was $61.11 for the day, down -0.63% from the previous closing price of $61.50. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 0.74 million shares were traded. JANX stock price reached its highest trading level at $63.86 during the session, while it also had its lowest trading level at $60.26.
Ratios:
Our analysis of JANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 38.80 and its Current Ratio is at 38.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 03 ’24 when Campbell David Alan sold 15,000 shares for $67.00 per share. The transaction valued at 1,005,000 led to the insider holds 242,054 shares of the business.
Campbell David Alan sold 25,000 shares of JANX for $1,289,879 on Nov 25 ’24. The President and CEO now owns 257,054 shares after completing the transaction at $51.60 per share. On Nov 01 ’24, another insider, Reardon Tighe, who serves as the FORMER OFFICER of the company, bought 5,202 shares for $53.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 3583050496 and an Enterprise Value of 2572436736. For the stock, the TTM Price-to-Sale (P/S) ratio is 268.94 while its Price-to-Book (P/B) ratio in mrq is 4.87. Its current Enterprise Value per Revenue stands at 197.137 whereas that against EBITDA is -30.667.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $7.79. The 50-Day Moving Average of the stock is 15.96%, while the 200-Day Moving Average is calculated to be 31.27%.
Shares Statistics:
JANX traded an average of 943.46K shares per day over the past three months and 2525330 shares per day over the past ten days. A total of 52.34M shares are outstanding, with a floating share count of 47.00M. Insiders hold about 18.68% of the company’s shares, while institutions hold 78.35% stake in the company. Shares short for JANX as of 1732838400 were 4477253 with a Short Ratio of 4.75, compared to 1730332800 on 4310503. Therefore, it implies a Short% of Shares Outstanding of 4477253 and a Short% of Float of 16.76.
